ACHN—To bring this thread back into context: Your contention is that, from reading the ACH-3422 patent and “other” publicly available sources, you can assert with high confidence that ACH-3422 will have efficacy and safety similar to Sovaldi.
I assert that your assertion is hogwash! If it were that easy to make such determinations, there wouldn’t be so many expensive failures in the development of HCV drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.